Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | TEK | Q02763 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 8/20 | 0.73 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.73 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.73 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.73 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.73 |
| ▸ | LTK | P29376 | 2/20 | 0.73 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.73 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.73 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.73 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.73 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.73 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.73 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.73 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.73 |
| ▸ | ABL1 | P00519 | 1/20 | 0.73 |
| ▸ | PIM1 | P11309 | 1/20 | 0.73 |
| ▸ | PRKACA | P17612 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30017084 | 1.00 | KDR (1.00) | KDRTEKEGFRABCG2ERBB2 | |
| SCHEMBL10000201 | 0.97 | KDR (0.94) | KDRTEKEGFRABCG2ERBB2 | |
| SCHEMBL30017298 | 0.90 | KDR (0.82) | KDRTEKEGFRABCG2ERBB2 | |
| Hydrochloric Acid SCHEMBL8808147 | 0.89 | KDR (0.80) | KDRTEKEGFRABCG2ERBB2 | |
| SCHEMBL30017767 | 0.88 | KDR (0.78) | KDRTEKEGFRABCG2ERBB2 | |
| SCHEMBL30017472 | 0.86 | KDR (0.76) | KDRTEKEGFRABCG2ERBB2 | |
| SCHEMBL22137832 | 0.86 | KDR (0.76) | KDRTEKEGFRABCG2ERBB2 | |
| SCHEMBL30017482 | 0.86 | KDR (0.75) | KDRTEKEGFRABCG2ERBB2 | |
| SCHEMBL15607573 | 0.86 | EGFR (0.78) | KDRTEKEGFRABCG2ERBB2 | |
| SCHEMBL8920 | 0.85 | EGFR (1.00) | KDRTEKEGFRABCG2ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-10548897-B2 | KSR antagonists | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-02-04 | — | — | US | disclosed |
| WO-2016168704-A1 | KSR ANTAGONISTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548897-B2 | KSR antagonists | KSR1, KSR2, KRAS | KDR 1123/4885TEK 891/4885EGFR 182/4885 |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | KDR 2712/4885TEK 2637/4885EGFR 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.